checkAd

     111  0 Kommentare VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM - Seite 4

    1The GSK proprietary AS01 adjuvant system contains QS-21 StimulonTM adjuvant licensed from Agenus Inc. (NASDAQ: AGEN)

    Lesen Sie auch


    Business Wire (engl.)
    0 Follower
    Autor folgen
    Seite 4 von 4

    VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM - Seite 4 VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data from its ongoing Phase 1/2a study of VBI-1901, …